Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407-Reference-Cited by-同舟云学术

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Published:2019-10 Issue: Volume:30 Page:v917-v918
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Paz-Ares L.,Langer C.J.,Novello S.,Halmos B.,Cheng Y.,Gadgeel S.M.,Hui R.,Sugawara S.,Borghaei H.,Cristescu R.,Aurora-Garg D.,Albright A.,Loboda A.,Kobie J.,Lunceford J.,Ayers M.,Lubiniecki G.M.,Pietanza M.C.,Piperdi B.,Garassino M.C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.078/30082380/mdz394.078.pdf

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB);2024-09-11

3. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer;Cancer Cell;2024-09

4. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

5. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07